Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

12 Aug 2008

Abstract excerpt

BACKGROUND: Apical Membrane Antigen 1 (AMA1), a polymorphic merozoite surface protein, is a leading blood-stage malaria vaccine candidate. This is the first reported use in humans of an investigational vaccine, AMA1-C1/Alhydrogel, with the novel adjuvant CPG 7909. METHODS: A phase 1 trial was conducted at the University of Rochester with 75 malaria-naive volunteers to assess the safety and immunogenicity of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Mosquito-borne diseases and control
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18698359
DOI: 10.1371/journal.pone.0002940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum MalariaPMID 18698359Read ↗

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Semantic proximity Read ↗

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.Semantic proximity Read ↗

Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.Semantic proximity Read ↗

Apical membrane antigen 1: a malaria vaccine candidate in reviewSemantic proximity Read ↗

Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future DirectionsSemantic proximity Read ↗

Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Semantic proximity Read ↗

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive IndividualsSemantic proximity Read ↗

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine OperationSemantic proximity Read ↗

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.Semantic proximity Read ↗

A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1Semantic proximity Read ↗

Targeting a malaria merozoite surface protein with mRNA vaccine generates multifunctional antibodiesSemantic proximity Read ↗

Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.